DalsnaFinance

Summit Therapeutics $SMMT

Health Care

Russell 1000 Florida
Create a scorecard
$17.41
+0.66 (+3.91%)
As of Oct 5, 2026, 2:54 PM EDT · cached
Price history
Loading chart…
Today's analyst average Analyst average over timeIndividual analyst targets Analyst history starts Sep 30, 2026, the first target we tracked for SMMT.

Summit Therapeutics (SMMT) is trading up at $17.41 (+3.91%), as of the latest quote. It is a Russell 1000 constituent in the Health Care sector.

IPO: March 5, 2015 · $9.90 offering · NASDAQ · View IPO details →

Analyst price targets on SMMT

One firm's current price target on Summit Therapeutics: $40 — 130% above the current $17.4. Each is tracked to its date and scored the same way a member's call is.

Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.

Summit Therapeutics revenue & net income history (FY2019–FY2025)

RevenueNet income
$57.1M−$511.2M−$1.08BFY2019 revenue: $57.1MFY2019 net income: $10.9M'19FY2020 revenue: $860.0KFY2020 net income: −$52.7M'20FY2021 revenue: $1.81MFY2021 net income: −$88.6M'21FY2022 revenue: $705.0KFY2022 net income: −$78.8M'22FY2023 revenue: $0FY2023 net income: −$614.9M'23FY2024 revenue: $0FY2024 net income: −$221.3M'24FY2025 net income: −$1.08B'25
Summit Therapeutics annual financial statements
FY2019Jan 2019FY2020Dec 2020FY2021Dec 2021FY2022Dec 2022FY2023Dec 2023FY2024Dec 2024FY2025Dec 2025
Income statement
Revenue$57.1M$860.0K$1.81M$705.0K$0$0—
Growth (year over year)—−98.5%+110.3%−61.0%−100.0%——
Operating income$5.39M−$53.2M−$86.2M−$72.1M−$609.6M−$226.0M—
Operating margin9.4%−6185.2%−4764.3%−10225.4%———
Net income$10.9M−$52.7M−$88.6M−$78.8M−$614.9M−$221.3M−$1.08B
Net margin19.0%−6127.6%−4897.8%−11174.8%———
EPS (diluted)$0.63−$0.76−$0.67−$0.41−$0.99−$0.31−$1.44
Balance sheet
Cash and equivalents$35.2M$66.4M$71.8M$348.6M$71.4M$104.9M$225.3M
Total assets—$102.5M$113.4M$664.2M$202.9M$435.6M$751.2M
Total liabilities—$23.0M$30.1M$537.5M$125.3M$46.8M$92.3M
Shareholders' equity$57.6M$79.5M$83.3M$126.7M$77.7M$388.7M$658.9M
Cash flow
Operating cash flow−$35.1M−$48.1M−$72.6M−$41.6M−$76.8M−$142.1M−$322.9M
Capital expenditure$157.0K$421.0K$306.0K$624.0K$128.0K$139.0K$657.0K
Free cash flow−$35.3M−$48.5M−$72.9M−$42.2M−$76.9M−$142.2M−$323.6M
Dividends paid$0$0—————

From Summit Therapeutics's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →

About Summit Therapeutics

Headquarters
Miami, Florida From SEC filings, Oct 2026

Recent News (1)

Other Health Care companies to compare with SMMT

Browse all companies →